Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.97, $0.01 worse than the analyst estimate of $4.98. Revenue for the quarter came in at $8.39 billion versus the consensus estimate of $8.35 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $19.10-$20.10, versus the consensus of $17.87. Amgen sees FY2024 revenue of $32.8-33.8 billion, versus the consensus of $30.3 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.